UK asks: which prescription drugs are least likely to be falsified?
This article was originally published in Scrip
Executive Summary
Which prescription medicines are least likely to be falsified, and which non-prescription drugs are most at risk? That's what the UK regulator, the MHRA, would like to know as it prepares to draw up its proposed "black" and "white" lists of products that in future either should or should not carry the "safety feature" required by the EU falsified medicines Directive (FMD).
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.